Breaking News

CureVac, GSK Initiate Next-Gen COVID Vax Trial

To further evaluate CureVac’s second-generation mRNA backbone, which has potential to be applied broadly in future vaccines against COVID variants.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

CureVac N.V., a global biopharmaceutical company developing medicines based on mRNA, initiated a Phase 1 study of COVID-19 second-generation mRNA vaccine candidate, CV2CoV, developed in collaboration with GlaxoSmithKline. The clinical trial will further evaluate the performance of CureVac’s second-generation mRNA backbone, which has the potential to be applied broadly in future vaccines against COVID-19 variants and other pathogens. 
   A preclinical study of CV2CoV in cynomolgus macaques demo...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters